Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study ID
NCT07391046
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Asplenia
  • Autoimmune Diseases
  • Cancer
  • Chronic Disease
  • Chronic Kidney Disease
  • Frailty
  • HIV Infection
  • Hematopoietic Stem Cell Transplantation
  • Immunocompromised
  • Inflammatory Bowel Disease
  • Solid Organ Transplantation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hospital-Based Vaccination Pathway — BIOLOGICAL
    Integration of vaccination counseling, prescription, and administration into hospital care pathways for vulnerable adult patients, including coordination with local public health vaccination services. No experimental vaccine is used; all vaccines are administered according to national guidelines.

Study Details

AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting. The study targets adult and elderly patients with chronic diseases or immunocompromising conditions who are eligible for vaccination according to national immunization guidelines. Vaccination is actively proposed during outpatient visits, hospital admissions, or at discharge and, when accepted, administered within the hospital or coordinated with local public health vaccination services. The study aims to evaluate the feasibility, uptake, and completion of hospital-based vaccination pathways and to support integration between hospital and territorial prevention services for vulnerable populations.

Key Dates

First listed
Feb 5, 2026
Start date
Feb 28, 2026
Status verified
Jan 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
1,500 participants (estimated)

Primary Outcome Measure

Vaccination Offer Rate [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Chronic kidney disease trialsHIV trialsNephrology trialsKidney disease trialsInfectious disease trials

Related Studies